SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales.

圣安东尼奥-（商业线）-bioAffinity Technologies，Inc。（纳斯达克股票代码：BIAF；BIAFW），一家生物技术公司，专注于需要无创，准确的检测早期癌症和肺部疾病的检测，今天宣布任命达拉斯J.科尔曼为国家销售总监。

Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division..

科尔曼先生在医疗销售和营销方面拥有超过15年的经验，最近担任奥林巴斯美国治疗解决方案部呼吸组合的执行账户经理。。

Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities.

向bioAffinity Technologies总裁兼首席执行官Maria Zannes报告，Coleman先生负责领导CyPath®Lung销售团队并采购新的商业机会。

“We are delighted to welcome Dallas to our management team in this newly created position. His experience and demonstrated track record in building strong relationships with our target customers and creating effective sales organizations is a timely and strategic fit as we ramp up the commercialization of CyPath® Lung, our noninvasive test for the detection of early-stage lung cancer,” Ms.

“我们很高兴欢迎达拉斯来到我们的管理团队这个新创建的职位。随着我们加快CyPath的商业化，他在与目标客户建立牢固关系和创建有效销售组织方面的经验和良好记录是及时和战略性的契合®Lung，我们用于检测早期肺癌的非侵入性检测，“女士。

Zannes said. “As a near-term priority, his expertise in developing commercial initiatives is expected to help drive the expansion of our pilot market launch across Texas and pave the way for the national rollout of CyPath® Lung.”.

Zannes说。“作为近期的优先事项，他在制定商业计划方面的专业知识有望帮助推动我们在德克萨斯州扩大试点市场的推广，并为全国推出CyPath®Lung铺平道路。”。

At Olympus America, Mr. Coleman was part of a team that launched new products, including spiration valves for COPD and emphysema patients, navigational bronchoscopy to access peripheral nodules, and ultrasound bronchoscopes used to sample lymph nodes for cancer staging, primarily marketing to pulmonologists, interventional pulmonologists, thoracic surgeons and physicians treating patients with lung disease.

在奥林巴斯美国，科尔曼先生是推出新产品团队的一员，该团队包括用于COPD和肺气肿患者的吸气阀，用于进入外周结节的导航支气管镜以及用于癌症分期淋巴结取样的超声支气管镜，主要销售给肺科医生，介入肺科医师，胸外科医生和医生治疗肺部疾病患者。

Prior to that, he held sales management positions at Caldera Medical, a medical device company focused on women’s health, and Ecolab, a global sustainability leader providing water, hygiene and hospital infection prevention solutions and services..

在此之前，他在专注于女性健康的医疗器械公司Caldera Medical和提供水，卫生和医院感染预防解决方案和服务的全球可持续发展领导者Ecolab担任销售管理职位。。

“My career has consistently revolved around extending the lives of patients and improving their quality of life. For the past five years, I have provided physicians and hospitals with innovative devices for the diagnosis and treatment of pulmonary diseases, including lung cancer,” Mr. Coleman said. “More than 14 million Americans are at high risk for lung cancer, and the opportunity to share CyPath® Lung with their care teams is highly motivating.

“我的职业生涯一直围绕着延长患者的生命和提高他们的生活质量而展开。过去五年来，我为医生和医院提供了诊断和治疗肺部疾病（包括肺癌）的创新设备，”科尔曼先生说。“超过1400万美国人患肺癌的风险很高，与他们的护理团队分享CyPath®lung的机会非常有动力。

I look forward to working with my new colleagues at bioAffinity to accelerate the rollout of this innovative product and help physicians treat lung cancer in its early stages, with better outcomes for patients.”.

我期待与bioAffinity的新同事合作，加快这一创新产品的推出，帮助医生在早期阶段治疗肺癌，为患者带来更好的疗效。

About CyPath® Lung

关于CyPath®Lung

CyPath® Lung uses flow cytometry to identify cell populations in patient sputum that indicate malignancy. Automated data analysis developed using proprietary artificial intelligence can help determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells.

CyPath®Lung使用流式细胞仪检测患者痰液中指示恶性肿瘤的细胞群。使用专有人工智能开发的自动数据分析可以帮助确定是否存在癌症或患者是否无癌症。CyPath®Lung含有荧光卟啉TCPP，优先被癌症和癌症相关细胞摄取。

In a clinical trial, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Half of all patients in the trial who had cancer were diagnosed in early Stages I or II. Diagnosing and treating early-stage cancer can increase patient survival and improve outcomes..

在一项临床试验中，CyPath®Lung在肺结节小于20毫米的高风险患者中检测肺癌的敏感性为92%，特异性为87%，准确性为88%。试验中所有患有癌症的患者中有一半在I或II期早期被诊断出来。诊断和治疗早期癌症可以提高患者的生存率并改善预后。。

About bioAffinity Technologies, Inc.

关于生物亲和技术公司。

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer.

bioAffinity Technologies，Inc。解决了对早期癌症和肺部疾病以及广谱癌症治疗的无创诊断的需求。该公司的第一款产品CyPath®Lung是一种非侵入性检测方法，对早期肺癌的检测具有高灵敏度，特异性和准确性。

CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio.

CyPath®Lung由生物亲和技术子公司Precision Pathology Laboratory Services作为实验室开发的测试（LDT）销售。该公司平台技术的研究和优化在其精确病理学实验室和德克萨斯大学圣安东尼奥分校进行。

For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and Twitter..

欲了解更多信息，请访问www.bioaffinitytech.com，并在LinkedIn，Facebook和Twitter上关注我们。。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.

本新闻稿中的某些声明构成联邦证券法含义内的“前瞻性声明”。诸如“可能”，“可能”，“将会”，“应该”，“相信”，“期望”，“预期”，“估计”，“继续”，“预测”，“预测”，“项目”，“计划，“意图”或类似的表达，或关于意图，信念或当前期望的陈述，都是前瞻性陈述。

These forward-looking statements are based upon current estimates and assumptions and include statements regarding Mr. Coleman’s expected contributions, including his expertise in developing commercial initiatives to drive the expansion of the Company’s pilot market launch across Texas, paving the way for the national rollout of CyPath® Lung, bringing CyPath® Lung to market, and helping physicians treat lung cancer in its early stages with better outcomes for patients.

这些前瞻性陈述基于当前的估计和假设，包括有关科尔曼先生预期贡献的陈述，包括他在制定商业计划方面的专业知识，以推动该公司在德克萨斯州扩大试点市场的推广，为全国推出CyPath铺平了道路®Lung，将CyPath®Lung推向市场，并帮助医生在早期阶段治疗肺癌，为患者带来更好的结果。

These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to successfully integrate Mr.

这些前瞻性陈述受到各种风险和不确定性的影响，其中许多风险和不确定性很难预测，可能导致实际结果与目前的预期和任何前瞻性陈述所阐述或暗示的假设大不相同。可能导致实际结果与当前预期大不相同的重要因素包括成功整合Mr的能力。

Coleman with the management team and derive the contributions expected from him and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.

科尔曼与管理团队合作，得出他预期的贡献以及公司在2022年12月31日结束的年度10-K年度报告中讨论的其他因素，以及随后向SEC提交的文件，包括随后的定期报告表格10-Q和8-K。这些前瞻性陈述是基于在作出这些陈述时存在的事实和条件以及对未来事实和条件的预测。

While t.

而t。